IJPR  articles are Indexed in SCOPUS (2010 - 2021)Click Here     *Five Years Citation in Google scholar (2016 - 2020) is. 1451*        Now IJPR is Q2 in SJR Ranking     Scopus Coverage of IJPR (2010-2021 Issue 1)          Journal is Currently Not Indexed in Scopus as on february 2021 list provided by scopus

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
No Data found.
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
One year follow up of kidney-transplanted patients who received Rabbit anti-thymocyteglobulinis

Author: LEILA MALEKMAKAN, TARANEHTADAYON, ZYNAB KARIMI, ALI ALRASHID
Abstract: Rabbit anti-thymocyteglobulinis (rATG) the most common drug, used for induction therapy in renal transplanted patient. Though, it still has not been approved by FDA. This studyaimed to evaluate the outcome of kidney transplanted patients who received rATG for induction.We gathered data of 54 patients who went under kidney transplantation and received rATG as induction therapy from 2013 till 2016. Also we followed these patients for one year and recorded their outcome. The mean age of patients was 40.2±11.6 and 32 patients (59.3%) were male. Generally, 66.7% (36 patients) of our patients experienced survived graft, 11.1% (6 patients) lost their graft, 3.7% (2 patients) experienced acute rejection and 20.4% (10 patients) of patients died during the study. Dead was occurred more in patients who suffered from both hypertension and diabetes and patients with cardiovascular disease (p=0.045, 0.023). Also graft loss was seen more in patients with re-transplant (p=0.012). Over all 3.8% (2 patients) of our patients developed malignancy. A wide variety of ranges reported for survival, graft loss, acute rejection and deathof patients who received rATG which is mostly due to small number of population. As a result, study with larger population must be done. Also malignancy is a lethal side effect of this drug that more studies must be done to determine the vulnerable patients.
Keyword: ESRD; rATG; Transplant
DOI: https://doi.org/10.31838/ijpr/2019.11.01.021
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free